BioTime Awarded Grant from the NIH

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it has been awarded a grant of up to $1.56 million from the Small Business Innovation Research program of the National Institutes of Health (NIH). The grant provides funding to further develop BioTime’s innovative, next generation vision restoration program for more advanced retinal d

Full Story →